Syndax Pharmaceuticals, Inc. (SNDX) News
Track canonical SquawkNews coverage tagged to SNDX, Syndax Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 04, 2026, 08:02 PM UTC
L
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
EQUITY | Jul 15, 2026, 12:56 PM UTC
L
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing
() -- Michael A Metzger, Director, Chief Executive Officer, on July 08, 2026, sold 32,375 shares in Syndax Pharmaceuticals (SNDX) for $784,776. Following the Form 4 filing with the SEC, Metzger has control over a total o
REGULATION | Jul 09, 2026, 08:57 PM UTC